Animal-Free Safety Assessment Collaboration’s Post

Join us for this webinar we're co-hosting with HealthforAnimals on the transition to non-animal-based batch release testing for vet vaccines. 🗓️ October 8 ⏰ 13:00-17:00 CEST What you can expect: 🔎 Theoretical aspects and regulatory incorporation of non-animal testing methods 🔎 Case studies showcasing successful animal testing substitutions 🔎 Key insights for regulatory agencies, public/private laboratories, and vaccine manufacturers worldwide Who should attend? Global or local manufacturers, regulatory bodies, representatives from VICH, WOAH, or FAO 📢 Registration now open! https://lnkd.in/gUHsYKgw #Webinar #AnimalFreeTesting #VeterinaryVaccines #RegulatoryReform

ACI Biosciences is currently enrolling dogs in a multicenter, randomized, placebo-controlled clinical trial to evaluate the safety and effectiveness of an oral therapy for the treatment of pruritus associated to allergic dermatitis. Take this short survey to connect with a study team member (https://lnkd.in/egiWKzc9 ) and learn more at https://lnkd.in/et8cCNh9. Together, we're improving the lives of our beloved pets! #acibiosciences #animalclinicalinvestigation #vetmed #veterinaryscience #clinicaltrials #veterinarymedicine

ACI Biosciences is currently enrolling dogs in a multicenter, randomized, placebo-controlled clinical trial to evaluate the safety and effectiveness of an oral therapy for the treatment of pruritus associated to allergic dermatitis. Take this short survey to connect with a study team member (https://lnkd.in/egiWKzc9 ) and learn more at https://lnkd.in/et8cCNh9. Together, we're improving the lives of our beloved pets! #acibiosciences #animalclinicalinvestigation #vetmed #veterinaryscience #clinicaltrials #veterinarymedicine #dogdermatitis

Learn more about the BINACLE Assay for Tetanus Neurotoxins: register for this 👇 #EDQM webinar on Nov 12. #animalfreescience #vaccines #newmethod #webinar

#IECV2024 The 2nd International Electronic Conference on Vaccines, 27–29 Nov 2024. Welcome our Committee Members in Session S2. Challenges of Developing a Dengue Vaccine: Dr. Uladzimir Karniychuk Department of Veterinary Biosciences, The Ohio State University, Columbus, USA Dr. Anna Nilsson Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden Dr. stelvio tonello Department of Medicine, Amedeo Avogadro University of Eastern Piedmont, Piedmont, Italy https://lnkd.in/geeXrg3d #vaccine #dengue #denguevaccine #virusserotypes #Secondaryinfections; #Hyperendemicareas #Tetravalentvaccines #Immuneresponses #Neutralizingantibodies #ADE #Immunopatogenesis

Controlling exposure to animal allergens is often a difficult undertaking. Check out our latest blog entry on how to evaluate the installed exposure controls at your facility: https://wix.to/kHVWf3B #newblogpost

𝐀 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐆𝐮𝐢𝐝𝐞 𝐭𝐨 “Veterinary Vaccines” [𝐏𝐃𝐅 – 𝐆𝐮𝐢𝐝𝐞] #Veterinary #vaccines are #products used to #stimulate an #animal’s immune system to produce immunity against a specific disease. Vaccines are typically composed of one or more viruses, bacteria, or other microorganisms that have been modified or killed in order to reduce or eliminate their pathogenicity, and/or toxoids which are toxins that have been rendered harmless. Vaccines may also contain adjuvants, which are substances that are added to the vaccine to improve its efficacy. ✅ 𝗚𝗿𝗮𝗯 𝗣𝗗𝗙 𝗙𝗼𝗿 𝗠𝗼𝗿𝗲 𝗗𝗲𝘁𝗮𝗶𝗹𝘀 >> https://lnkd.in/gr7hpRje 𝐊𝐞𝐲 𝐓𝐫𝐞𝐧𝐝𝐬 The key trends in Veterinary Vaccines technology are: 1. The development of safer and more effective vaccines 2. The use of new technologies to improve vaccine efficacy 3. The development of new delivery systems for vaccines 4. The use of adjuvants to improve vaccine efficacy ✅𝐓𝐨𝐩 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐦𝐞𝐧𝐭𝐢𝐨𝐧𝐞𝐝 𝐚𝐬 𝐛𝐞𝐥𝐨𝐰: Merck & Co., Inc. Zoetis. Ceva Santé Animale Sanofi S.A. ROMVACCINE INC Vaxxinova Merial Boehringer Ingelheim HIPRA #AnimalHealth #VetVaccines #VeterinaryCare #AnimalWellness #PetHealth #LivestockHealth #AnimalVaccines #AnimalScience #PetCare #VeterinaryMedicine #Zoetis #MerckAnimalHealth #BoehringerIngelheim #ElancoAnimalHealth

ACI Biosciences is currently enrolling dogs in a multicenter, randomized, placebo-controlled clinical trial to evaluate the safety and effectiveness of an oral therapy for the treatment of pruritus associated with allergic dermatitis. Take this short survey to connect with a study team member (https://lnkd.in/egiWKzc9 ) and learn more at https://lnkd.in/et8cCNh9. Together, we're improving the lives of our beloved pets! #acibiosciences #animalclinicalinvestigation #vetmed #veterinaryscience #clinicaltrials #veterinarymedicine #coonhound #coondogday

Progress! Effective July 1st, 2024, the Indian Pharmacopoeia Commission (IPC) will now allow requests to waive the Target Animal Batch Safety Test (TABST) for veterinary vaccines. The waiver is allowed or can be requested based on specific conditions that guarantee vaccines quality and consistency of the production as per the VICH Guidelines. By recognizing the shortfalls of the TABST and allowing the test to be waived, India is a step closer to aligning itself with international veterinary vaccine testing standards, joining Brazil, Europe, Canada, the US, Japan, and others. AFSA has been collaborating with many local and international stakeholders to secure the implementation of the waiver and promote global alignment of testing requirements for veterinary vaccines. We thank all stakeholders for their collaborative efforts in achieving this landmark milestone for India and veterinary vaccine manufacturers. This waiver follows a series of progressive decisions by the IPC: 2018 ➡ Rabbit Pyrogen Test replaced with the Bacterial Endotoxin Test (BET), followed by inclusion of the Monocyte Activation Test (MAT) 2020 ➡ Abnormal Toxicity Test (ATT) removed for almost all human vaccines in Indian Pharmacopoeia monographs Read more in AFSA partner, Humane Society International India’s, press release: https://lnkd.in/dFiTQbWD #animalfreescience #veterinaryvaccines #vaccines #batchsafetytesting #regulatoryupdate #TABST #progress #india